Invasive fungal infections (IFI) are a significant cause of morbidity and mortality after haematopoietic stem cell transplantation (HSCT). 1 Patients with a history of IFI are thought to be at a high risk of suffering reactivation during subsequent chemotherapy and HSCT. 2, 3 We have allografted three patients with a history of IFI within the preceding 4-6 months.
A 44-year-old woman with Ph þ ALL developed rightsided facial swelling and loss of vision during induction chemotherapy. Ethmoid sinusitis was detected on MRI. Cultures of right ethmoid biopsy grew mucor (Abcedea corymebifera), which was sensitive to amphotericin and itraconazole. She was treated with liposomal amphotericin (LA) 5 mg/kg for 2 months and G-CSF during neutropenia. She responded well with reduction in facial swelling, and complete resolution of fever and inflammatory markers. Vision did not recover. After 5 months, she underwent conventional-intensity HSCT from an HLA-matched sibling, receiving itraconazole 200 mg twice daily and liposomal amphotericin 100 mg every other day prophylactically. LA was stopped on day þ 20 but itraconazole was continued. LA was restarted on day þ 35 at a dose of 1 mg/kg every other day when systemic steroids were administered for GVHD, and was discontinued on day þ 68. She is currently 10 months post transplant, in molecular remission and with no evidence of active fungal infection.
A 33-year-old man with AML relapsing after an autograft developed pneumonia during FLAG salvage chemotherapy. CT scan of his chest showed a cavitating lesion suggestive of aspergillus pneumonia ( Figure 1 ). Lung biopsy showed evidence of infection and fibrosis but no organism was identified. There was good clinical response to LA and G-CSF. He received LA 100 mg thrice a week prophylactically during a conventional-intensity allograft from an unrelated donor. The LA dose was increased to 100 mg daily due to prolonged, unresponsive neutropenic fever. CT scan of the chest showed unchanged nodules and cavitating lesions. He was considered too unwell to have a 
bronchoalveolar lavage. The LA dose was increased to 3 mg/kg daily and continued for a total of 7 weeks. He was also commenced on itraconazole. There was a good clinical response with resolution of fever. The CT scan remained unchanged. Itraconazole was continued for 18 months, including throughout treatment for cutaneous GVHD requiring steroids. He is currently 49 months post transplant, in remission and without any clinical evidence of a fungal infection.
A 22-year-old man with AML developed neutropenic fever with patchy ground glass lung shadows on CT during induction chemotherapy. A CT scan was repeated 20 days after treatment with LA. This showed progressive lesions in the lung, liver and spleen. Cultures from the bronchoalveolar lavage fluid grew Candida albicans. Liver biopsy showed necrotising granulomatous tissue but no organism. Voriconazole was added. He had a good clinical response to the combination of LA and voriconazole. CT showed resolution of pulmonary lesions but not the hepatic and splenic lesions. After 4 months, he underwent a conventional-intensity haploidentical transplant. LA 100 mg daily (days 7-28) and voriconazole (for 3 months) were administered prophylactically. Ataxia and diplopia developed 5 months post transplant. CSF showed high protein but no organism. MRI scan of the head and neck demonstrated a sizeable mass on the left side of the adenoid pad extending to the upper tonsillar fossa. Biopsy of this mass showed a low-grade active, chronic rhinitis but no organism. As the illness responded to LA, it was presumed to be of fungal aetiology. Fungal prophylaxis was discontinued 6 months post transplant. He is currently 15 months post transplant, in remission and with no evidence of fungal infection.
The occurrence of IFI after allogeneic HSCT is associated with acute GVHD, immunosuppression, ATG, TBI-conditioning regimens, HLA-mismatched grafts, and fungal colonisation pre-transplant. 4 All our patients had received TBI, had fungal colonisation pre-transplant, and had acute GVHD requiring steroids. Patient 3 also had ALG and had undergone a haploidentical transplant. 5 As the clinical course of our patients shows, there is a high risk of reactivation of fungal infections during steroid therapy for GVHD. While others have described successful use of HSCT in patients with a history of IFI, 6-9 the number of such reports is small and fungal prophylaxis has not been uniform. Also, none of these reports describe the management of IFI during GVHD and steroid therapy. Our experience shows that with early, aggressive and prolonged use of appropriate antifungal agents, allogeneic HSCT can be performed safely. 
